Prevention of cardiomyopathy in transfusion-dependent homozygous thalassaemia today and the role of cardiac magnetic resonance imaging

Advances in Hematology

Volumn 2009, Issue , 2009, Pages

  Aessopos, Athanassios ^a   Berdoukas, Vasilios ^a   Tsironi, Maria ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE;

CARDIOMYOPATHY; CAUSE OF DEATH; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG EFFICACY; HEART PROTECTION; HUMAN; IRON CHELATION; IRON OVERLOAD; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SURVIVAL; THALASSEMIA MAJOR;

EID: 77953413532     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2009/964897     Document Type: Review

References (29)

1. Modell B., Khan M., Darlison M., Survival in β-thalassaemia major in the UK: data from the UK thalassaemia register The Lancet 2000 355 9220 2051 2052 (Pubitemid 30339248)
2. Borgna-Pignatti C., Rigolotto S., De Stefano P., Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine Haematologica 2004 89 10 1187 1193 (Pubitemid 39390442)
3. Caro J. J., Ward A., Green T. C., Impact of thalassemia major on patients and their families Acta Haematologica 2002 107 3 150 157 (Pubitemid 34455079)
4. Aessopos A., Farmakis D., Hatziliami A., Cardiac status in well-treated patients with thalassemia major European Journal of Haematology 2004 73 5 359 366 (Pubitemid 39349917)
5. Olivieri N. F., Nathan D. G., Macmillan J. H., Survival in medically treated patients with homozygous β-thalassemia The New England Journal of Medicine 1994 331 9 574 578 (Pubitemid 24265699)
6. Anderson L. J., Holden S., Davis B., Cardiovascular T2-star (T 2) magnetic resonance for the early diagnosis of myocardial iron overload European Heart Journal 2001 22 23 2171 2179 (Pubitemid 33139463)
7. Wood J. C., Tyszka J. M., Carson S., Nelson M. D. Jr., Coates T. D., Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease Blood 2004 103 5 1934 1936 (Pubitemid 38268994)
8. Aessopos A., Fragodimitri C., Karabatsos F., Cardiac magnetic resonance imaging R 2 assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia Haematologica 2007 92 1 131 132 (Pubitemid 46232670)
9. Tanner M. A., Galanello R., Dessi C., Myocardial iron loading in patients with thalassemia major on deferoxamine chelation Journal of Cardiovascular Magnetic Resonance 2006 8 3 543 547
10. Cunningham M. J., Macklin E. A., Neufeld E. J., Cohen A. R., Complications of β-thalassemia major in North America Blood 2004 104 1 34 39
11. Aessopos A., Giakoumis A., Fragodimitri C., Correlation of echocardiography parameters with cardiac magnetic resonance imaging in transfusion-dependent thalassaemia major European Journal of Haematology 2007 78 1 58 65 (Pubitemid 46018560)
12. Olivieri N. F., Brittenham G. M., Iron-chelating therapy and the treatment of thalassemia Blood 1997 89 3 739 761
13. Berdoukas V., Dakin C., Freeman A., Fraser I., Aessopos A., Bohane T., Lack of correlation between iron overload cardiac dysfunction and needle liver biopsy iron concentration Haematologica 2005 90 5 685 686 (Pubitemid 40780888)
14. Piga A.,. personal communications
15. Fitchett D. H., Coltart D. J., Littler W. A., Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium Cardiovascular Research 1980 14 12 719 724
16. Barosi G., Arbustini E., Gavazzi A., Grasso M., Pucci A., Myocardial iron grading by endomyocardial biopsy. A clinico-pathologic study on iron overloaded patients European Journal of Haematology 1989 42 4 382 388 (Pubitemid 19131449)
17. Anderson L. J., Holden S., Davis B., Cardiovascular T2-star (T2) magnetic resonance for the early diagnosis of myocardial iron overload European Heart Journal 2001 22 23 2171 2179 (Pubitemid 33139463)
18. Wood J. C., Enriquez C., Ghugre N., MRI R2 and R2mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients Blood 2005 106 4 1460 1465 (Pubitemid 41129616)
19. Voskaridou E., Douskou M., Terpos E., Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease British Journal of Haematology 2004 126 5 736 742 (Pubitemid 39221312)
20. Ooi G. C., Khong P. L., Chan G. C. F., Magnetic resonance screening of iron status in transfusion-dependent β-thalassaemia patients British Journal of Haematology 2004 124 3 385 390 (Pubitemid 38167991)
21. Olivieri N. F., Brittenham G. M., Armstrong S. A. M., First prospective randomized trial of the iron chelators deferiprone (L1) and deferoxamine Blood 1995 86 10, supplement 1. abstract no. 249a
22. Westwood M. A., Firmin D. N., Gildo M., Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia International Journal of Cardiovascular Imaging 2005 21 5 531 538 (Pubitemid 41435154)
23. Ghugre N. R., Enriquez C. M., Coates T. D., Nelson M. D. Jr., Wood J. C., Improved R 2 measurement in myocardial iron overload Journal of Magnetic Resonance Imaging 2006 23 1 9 16 (Pubitemid 43100712)
24. Tanner M. A., Galanello R., Dessi C., A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance Circulation 2007 115 14 1876 1884 (Pubitemid 46598901)
25. Pennell D. J., Berdoukas V., Karagiorga M., Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis Blood 2006 107 9 3738 3744
26. Peng C.-T., Chow K.-C., Chen J.-H., Chiang Y.-P., Lin T.-Y., Tsai C.-H., Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan European Journal of Haematology 2003 70 6 392 397
27. Cappellini M. D., Cohen A., Piga A., A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia Blood 2006 107 9 3455 3462
28. Anderson L. J., Westwood M. A., Holden S., Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2*cardiovascular magnetic resonance British Journal of Haematology 2004 127 3 348 355 (Pubitemid 39468951)
29. Borgna-Pignatti C., Cappellini M. D., De Stefano P., Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major Blood 2006 107 9 3733 3737